

ADVERTISEMENT



INVITATION TO INVEST



SUBSCRIPTION PERIOD: 9-23 July 2026

IMPORTANT INFORMATION

This information brochure constitutes marketing material and is not a prospectus within the meaning of Regulation (EU) 2017/1129 of the European Parliament and of the Council. The offering is exempt from the prospectus requirement in accordance with applicable regulations. Any invitation to subscribe for securities in Prostatype Genomics AB ("Prostatype Genomics" or the "Company") is made solely through the information memorandum published in July 2026, which is available on the Company's website at www.prostatypegenomics.com. Investors are advised to read the information memorandum in its entirety before making an investment decision.

Investing in securities involves risks, and an investment decision is subject to uncertainty. Investors may lose all or part of their invested capital. The shares of Prostatype Genomics are listed on Nasdaq First North Growth Market, which is a multilateral trading facility (MTF) and not a regulated market. Companies whose shares are traded on Nasdaq First North Growth Market are not subject to the same requirements as companies listed on a regulated market. Please note that historical performance is not a reliable indicator of future results.

This information brochure may contain forward-looking statements, forecasts, and assumptions regarding the Company's future operations, financial position, and results. Such statements are not guarantees of future performance and involve risks, uncertainties, and factors beyond the Company's control. Actual results may differ materially from those expressed or implied in such forward-looking statements.

This information brochure may not be distributed, published, or released in or into the United States, the United Kingdom, Australia, Japan, Canada, New Zealand, South Africa, Hong Kong, Switzerland, or Singapore. The information brochure may not be sent to persons in these countries or any other jurisdiction where it would be unlawful to deliver unit rights, BTUs (paid subscribed units), new shares, or warrants, except in compliance with applicable law and provided that no additional prospectus, registration, or other measures are required beyond those imposed under Swedish law.

Except as expressly stated otherwise in the information memorandum, unit rights, BTUs, new shares, or warrants may not be offered, sold, transferred, or delivered, directly or indirectly, in or into any of the countries listed above unless approved by the Company and carried out in compliance with applicable laws and regulations in the relevant jurisdiction.

NAVIA
CORPORATE FINANCE

Birchtree Advisory

INVESTMENT HIGHLIGHTS

Positioned for commercial breakthrough in the USA – Over the past several years, Prostatype Genomics has established the regulatory and commercial foundations necessary for a broad launch of Prostatype® in the United States. The Company has secured laboratory and billing partnerships and is engaged in advanced discussions regarding commercial scale-up.

Ongoing Medicare process with significant commercial potential – The Company is currently progressing through an advanced and constructive Medicare reimbursement process in the United States. The application is being evaluated within an existing regulatory framework with an established reimbursement level of USD 3,783 per test performed, providing a solid foundation for attractive future revenue opportunities.

Big and growing addressable market – The U.S. represents the largest global market for prognostic prostate cancer biomarkers. In contrast to many European markets, this category of biomarkers is included in national clinical practice guidelines in the United States, providing a strong foundation for widespread clinical adoption and commercial uptake.

Clear clinical need and strong patient benefit – Prostatype® addresses a significant unmet medical need, as many patients today are overtreated with surgery or radiation therapy despite having a low risk of developing life-threatening disease. The test supports more informed and individualized treatment decisions and may help reduce the risk of serious lifelong side effects, including erectile dysfunction and urinary incontinence.

Short path to revenue generation – Prostatype® is already being used at selected hospitals in the United States. With the necessary regulatory and commercial infrastructure in place, the Company believes that the time from Medicare approval to commercial sales will be relatively short.

Clear value inflecting milestones – The ongoing Medicare reimbursement process represents a key value driver for the Company. A positive reimbursement decision is expected to facilitate accelerated commercialization and broader market penetration in the United States.

Capitalization for the next growth phase – The Rights Issue is being carried out to support the Company's continued development, complete the Medicare reimbursement process, and enable the scaling of its commercial operations and organization in the United States.

WORDS FROM FREDRIK RICKMAN



Prostate cancer is the most common form of cancer among men and remains an area where overtreatment continues to represent a significant clinical challenge. Each year, a large number of patients undergo radical treatment even though their cancer would never have progressed to a life-threatening condition. For many individuals, the consequences are lifelong side effects that can significantly impair quality of life. This is precisely the problem that Prostatype® was developed to address.

At Prostatype Genomics, our ambition is clear – to contribute to more informed treatment decisions through precision diagnostics and thereby ensure that the right patient receives the right treatment at the right time. Through our genetic prognostic biomarker, Prostatype®, healthcare providers can more accurately identify which patients require radical treatment and which patients may avoid unnecessary interventions.

Over the past two years, we have taken important steps to establish the Company in the United States, the world's largest and most important market for prognostic biomarkers in prostate cancer. Today, we have the regulatory and commercial foundations in place to accelerate sales in the U.S., including established laboratory and billing partnerships as well as ongoing discussions regarding commercial scale-up. Prostatype® is already being used at selected hospitals in the United States, providing an important foundation for broader commercialization.

Our primary focus is now the ongoing Medicare reimbursement process. The dialogue with Medicare continues to progress constructively and intensively, with regular meetings and supplementary review processes underway. The reimbursement level within the applicable regulatory framework amounts to USD 3,783 per completed test, representing significant commercial potential for the Company. While the timing of a final decision remains difficult to predict with certainty, our assessment continues to be that the conditions for obtaining reimbursement approval are favorable.

To support our continued development and enable rapid commercial scale-up, we are now conducting a Rights Issue. The capital raise is intended both to strengthen the Company's financial position through the repayment of bridge financing and to fund the completion of the Medicare reimbursement process, while preparing the organization for broader commercialization in the United States. With additional capital, we believe the Company is well positioned to create long-term value for patients, healthcare providers, and shareholders.

We are at a pivotal stage in the Company's development. With a clear clinical value proposition, a large addressable market, and an organization prepared for commercialization, we look to the future with confidence and welcome both existing and new shareholders to join us on the next phase of our journey.



Fredrik Rickman, CEO, Prostatype Genomics AB

PROSTATYPE GENOMICS

Prostatype Genomics is built on more than 15 years of research into the genetic mechanisms of prostate cancer. The Company was founded in 2007 as a spin-off from the Cancer Center Karolinska at the Karolinska Institutet in Stockholm. This research has resulted in the development of the Prostatype® Test System, an IVDR-approved product that is now commercially available. In addition to the European market, Prostatype® has also been introduced in the United States, where the test is used in clinical practice. As a result, the necessary regulatory and commercial foundations for the U.S. market are already in place.

Prostatype® is a patented genetic test used to assess prognosis in prostate cancer and provide additional decision support for treatment strategy selection. The test analyzes gene expression in a patient's prostate biopsy, with a particular focus on genes associated with embryonic cancer stem cells. As the analysis is performed on tissue samples already collected during diagnosis, no additional sampling is required. This contributes to a smoother patient pathway as well as a more precise basis for treatment decisions.

The test is designed to complement the diagnostic and prognostic methods currently used in routine clinical care. According to the Board's assessment, Prostatype® is the only patented prostate cancer test that focuses on gene expression related to embryonic cancer stem cells while also being designed for use by independent hospitals and laboratories.

By analyzing gene activity in prostate cancer cells, combined with advanced algorithms and extensive data processing, Prostatype® generates decision support for personalized treatment of patients with confirmed prostate cancer. Through the use of artificial intelligence, the test provides a more accurate prognostic assessment and classifies patients into different risk categories. This helps reduce the risk of both overtreatment and undertreatment, thereby potentially limiting serious and long-lasting side effects such as erectile dysfunction and urinary incontinence.

The Prostatype® Test System consists of several integrated components: the Prostatype® RT-qPCR Kit, patient databases and analysis algorithms, the web-based system PWS (Prostatype Web System), and the associated risk indicator P-score.

Prostatype Genomics has initiated the commercialization of Prostatype® and follows a focused strategy aimed at cost-efficiently maximizing market penetration in selected markets, with the objective of generating recurring revenue and validating the business model across different geographic regions. In addition to targeted sales efforts, a key component of the strategy is to strengthen the scientific foundation through local validation studies, which are often a prerequisite for clinical adoption.

The United States is the Company's primary strategic focus, alongside operations in selected EMEA markets in Northern Europe, with particular emphasis on Sweden, Spain, and Italy.

Over the past several years, the Company has systematically worked on-site in various countries to map and evaluate different markets and approaches from a commercial perspective in order to determine whether the following criteria are met, or can be met in the near term:

- clinical acceptance of genetic testing in prostate cancer and confirmed clinical utility, and
- market acceptance, demonstrated through clinics evaluating and beginning to use Prostatype®



MOTIVE FOR THE OFFERING

In order to commercialize and market Prostatype Genomics' genetic test Prostatype® in the United States with greater force, the Company is awaiting Medicare reimbursement approval. The Company's application was submitted in September 2024, and since then responses to follow-up questions have been provided. The timing of approval is difficult for the Company to estimate, as it depends on processes within U.S. regulatory authorities. The Company is working with Swedish and U.S. legal advisers in the matter, and the assessment is that it is reasonable to assume that approval may be obtained during the current year. With Medicare approval in place, the Board's assessment is that Prostatype Genomics will be well positioned to commercialize Prostatype® in the United States.

To finance the repayment of outstanding bridge loans and related interest, as well as the Company's continued development described above, Prostatype Genomics is carrying out a rights issue with a maximum issue volume of approximately SEK 47.4 million. Through the funds potentially raised in full in the rights issue (after issue costs), the Company intends to finance the following activities:

- Medicare reimbursement process
- Commercialization activities in the United States and Europe, as well as strengthening of working capital and ongoing operational activities
- Repayment/conversion of bridge loans and payment of interest expenses
- Settlement of supplier payables under payment plans

Through the funds potentially raised via warrants of series TO6 (after issue costs), the Company intends to finance the following activity:

- Scaling of commercialization and organization in the United States, as well as ongoing operating expenses

Through the funds potentially raised via warrants of series TO7 (after issue costs), the Company intends to finance the following activity:

- Scaling of commercialization and organization in the United States, as well as ongoing operating expenses

It is the Board's assessment that the net proceeds from a fully subscribed initial rights issue, together with full exercise of warrants of series TO6 and TO7 at the highest exercise price, are sufficient to finance the Company's ongoing operations and plans through Q4 2027. In the event of an undersubscribed rights issue, Prostatype Genomics will – after repayment of the aforementioned bridge loan, including setup fees and interest costs related to the loan – prioritize activities focused on the United States.

THE OFFERING IN BRIEF

Subscription period: 9-23 July 2026.

Subscription price: SEK 0.80 per unit, corresponding to SEK 0.10 per share. Warrants of series TO6 and warrants of series TO7 are issued free of charge.

Issue volume: initially a maximum of approximately SEK 47.4 million before transaction-related costs. Through the attached warrants of series TO6 and TO7 issued in connection with the rights issue, the Company may receive additional proceeds of up to approximately SEK 59.2 million in total.

Subscription- and underwriting commitments: the rights issue is contractually secured to approximately 91.3 percent of the total issue volume (corresponding to approximately SEK 43.2 million) through subscription commitments and bottom- and top-down underwriting undertakings.

Warrants of series TO6: one (1) TO6 entitles the holder to subscribe for one (1) new share. The exercise price for warrants of series TO6 warrants will be SEK 0.10 per share, corresponding to both the subscription price per share in the rights issue and the share's quota value. Upon full exercise of warrants of series TO6 at the maximum exercise price, the Company may receive approximately SEK 11.8 million before deduction of issue costs, which are estimated to amount to a maximum of approximately SEK 0.6 million.

Warrants of series TO7: one (1) TO7 entitles the holder to subscribe for one (1) new share. The exercise period for TO7 is event-driven, based on the receipt of Medicare reimbursement approval. The exercise price shall correspond to 70 percent of the volume-weighted average price of the Company's share on Nasdaq First North Growth Market during a measurement period of ten (10) trading days preceding the Company's announcement of approval of the Company's Medicare application. However, the minimum exercise price will be SEK 0.10 per share and the maximum exercise price will be SEK 0.20 per share. According to the terms of the warrants of series TO7, the exercise period will commence no earlier than 1 September 2026 and no later than 7 December 2026. Upon full exercise of warrants of series TO7 at the maximum exercise price, the Company may receive approximately SEK 47.2 million before deduction of issue costs, which are estimated to amount to a maximum of approximately SEK 2.2 million.

TERMS & CONDITIONS

PRE-EMPTIVE RIGHT TO SUBSCRIBE

Shareholders who are registered in the share register maintained by Euroclear on behalf of the Company as of the record date, 7 July 2026, shall have preferential rights to subscribe for new units in proportion to the number of shares held on the record date. For each existing share held on the record date, one (1) unit right will be received. The unit rights entitle the holder to subscribe for new units with preferential rights, whereby one (1) unit right entitles the holder to subscribe for one (1) new unit. One (1) unit consists of eight (8) shares, two (2) warrants of series TO6, and four (4) warrants of series TO7.

ISSUE VOLUME

The Offering comprises a maximum of 59,189,321 units (corresponding to a total of 473,514,568 shares, 118,378,642 warrants of series TO6, and 236,757,284 warrants of series TO7 issued free of charge). The total issue initial proceeds amount to a maximum of approximately SEK 47.4 million before transaction costs. Through the initial part of the Rights Issue, the share capital may increase by a maximum of SEK 47,351,456.80.

SUBSCRIPTION PRICE

The subscription price is SEK 0.80 per unit, corresponding to a price of SEK 0.10 per share. Warrants of series TO6 and warrants of series TO7 are issued free of charge. No brokerage commission will be charged.

WARRANTS OF SERIES TO6

Warrants of series TO6 are issued free of charge. One (1) warrant of series TO6 entitles the holder to subscribe for one (1) new share. The exercise price for warrants of series TO6 warrants will be SEK 0.10 per share, corresponding to both the subscription price per share in the rights issue and the share's quota value.

Warrants of series TO6 may be exercised for subscription of new shares in Prostatype Genomics during the period from 1 September 2026 up to and including 15 September 2026. Warrants of series TO6 will be admitted to trading on Nasdaq First North Growth Market. The last day of trading in warrants of series TO6 is expected to be 11 September 2026.

Upon full exercise of warrants of series TO6, the Company's share capital will increase by SEK 11,837,864.20. Upon full exercise of warrants of series TO6 at the maximum exercise price, the Company will receive approximately SEK 11.8 million before deduction of issue costs.

The complete terms and conditions for TO6 are available on the Company's website.

WARRANTS OF SERIES TO7

Warrants of series TO7 are issued free of charge. One (1) warrant of series TO7 entitles the holder to subscribe for one (1) new share. The exercise period for warrants of series TO7 is event-driven and contingent upon receipt of Medicare approval. The exercise price shall correspond to 70 percent of the volume-weighted average price (VWAP) of the Company's share on Nasdaq First North Growth Market during a measurement period of ten (10) trading days preceding the Company's announcement of approval of its Medicare application. However, the minimum exercise price shall be SEK 0.10 and the maximum exercise price shall be SEK 0.20.

Primarily, an exercise period of ten (10) trading days shall commence three (3) trading days after approval of the Medicare application has been announced by the Company through a press release, but not earlier than 1 September 2026 and not later than 7 December 2026.

Alternatively, if approval of the Company's Medicare application has not been obtained and an exercise period has not been determined within the timeframe described above, the exercise period shall commence on 7 December 2026 and continue for ten (10) trading days up to and including 21 December 2026. In such case, the exercise price shall correspond to 70 percent of the volume-weighted average price (VWAP) of the Company's share during the ten trading days ending two days prior to the commencement of the exercise period on 7 December 2026.

The above terms mean that the ten (10) trading day exercise period for TO7 may commence no earlier than 1 September 2026 and no later than 7 December 2026.

Upon full exercise of warrants of series TO7, the Company's share capital will increase by SEK 23,675,728.40. Upon full exercise of warrants of series TO7 at the maximum exercise price, the Company will receive approximately SEK 47.4 million before deduction of issue costs.

TO7 warrants are intended to be admitted to trading on Nasdaq First North Growth Market. The last day of trading in TO7 is expected to be no later than 17 December 2026.

The complete terms and conditions for TO7 are available on the Company's website.

RECORD DATE

The record date with Euroclear Sweden AB ("Euroclear") for participation in the Rights Issue was 7 July 2026. The last day of trading in the Company's shares with the right to participate in the Rights Issue was 3 July 2026. The first day of trading in the Company's shares without the right to participate in the Rights Issue was 6 July 2026.

SUBSCRIPTION PERIOD

Subscription for new units with the support of unit rights shall take place during the period from 9 July 2026 up to and including 23 July 2026. The Board of Directors reserves the right to extend the subscription period. Any such extension will be announced by the Company through a press release no later than 23 July 2026.

UNIT RIGHTS

For each existing share held on the record date, one (1) unit right will be received. Unit rights entitle the holder to subscribe for new units with preferential rights, whereby one (1) unit right entitles the holder to subscribe for one (1) new unit consisting of eight (8) shares, two (2) warrants of series TO6, and four (4) warrants of series TO7.

TRADING IN UNIT RIGHTS

Trading in unit rights will take place on Nasdaq First North Growth Market during the period from 9 July 2026 up to and including 20 July 2026. Shareholders should contact their bank or other nominee with the necessary authorizations to buy or sell

unit rights. Unit rights acquired during the above trading period carry the same entitlement to subscribe for units during the subscription period as the unit rights received by shareholders based on their holdings in the Company on the record date.

UNEXERCISED UNIT RIGHTS

Unit rights that are not sold by 20 July 2026 or exercised for subscription of units by 23 July 2026 will be removed from all securities accounts (VP accounts) without compensation. No separate notification will be issued regarding the removal of unit rights.

POTENTIAL OVER-ALLOTMENT ISSUE

In the event that the Rights Issue is oversubscribed and individuals or entities that have entered into subscription commitments without preferential rights are not allocated units (in whole or in part) to a sufficient extent to fulfil their commitments, the Company intends to resolve on a separate directed issue of units (a so-called over-allotment issue). The terms of any such directed issue of units will correspond to the terms of the Rights Issue. The potential over-allotment issue may comprise up to an additional 4,230,843 units, corresponding to 33,846,744 shares, 8,461,686 warrants of series TO6, and 16,923,372 warrants of series TO7. Through the potential over-allotment issue, the Company's share capital may increase by a maximum of SEK 5,923,180.20, of which SEK 3,384,674.40 relates to the initial part of the Rights Issue, SEK 846,168.60 relates to warrants of series TO6, and SEK 1,692,337.20 relates to warrants of series TO7. In connection with the issue resolution, the Board of Directors shall determine allocation in accordance with the allocation principles applicable to the Rights Issue. The potential over-allotment issue may result in a maximum dilution of 5.9 percent, 1.2 percent, and 1.8 percent, respectively, through the initial issue of shares, the exercise of warrants of series TO6, and the exercise of warrants of series TO7.

ISSUE STATEMENT AND SUBSCRIPTION

Directly registered shareholders

Shareholders, or representatives of shareholders, who on the record date, 7 July 2026, were registered with Euroclear, will receive a pre-printed issue statement together with a payment form. Information will be available on Vator Securities' website (<https://vatorsecurities.se/sv/offers>) and on the Company's website (www.prostatypegenomics.com). Persons included in the separate register maintained in connection with the share register for pledgees and others will not receive any information but will be notified separately. No VP advice note showing the registration of unit rights on shareholders' VP accounts will be distributed.

SUBSCRIPTION WITH PREFERENTIAL RIGHT

Subscription with preferential rights shall be made through simultaneous cash payment no later than 23 July 2026. Subscription by payment may be made either using the pre-printed payment form enclosed with the issue statement or by subscribing via Vator Securities' website in accordance with one of the following two alternatives:

Issue statement (pre-printed payment form from Euroclear)

If all unit rights received on the record date are to be exercised for subscription, only the pre-printed payment form shall be used as the basis for subscription through cash payment.

Special subscription form

If a number of unit rights other than those stated on the pre-printed payment form from Euroclear are exercised, the special application form must be used. Subscription through payment shall be made in accordance with the instructions stated on the special application form. In such case, the pre-printed payment form from Euroclear shall not be used. A special application form may be ordered from Vator Securities by telephone or e-mail.

INFORMATION TO BANKS/NOMINEES REGARDING SUBSCRIPTION

On the first day of the subscription period, Vator Securities will distribute an e-mail containing a brief summary of the Offering together with application forms that may be used by all banks/nominees for subscriptions both with and without the support of unit rights on behalf of their underlying clients.

Vator Securities reserves the right to disregard application forms submitted by regular mail, as receipt before the final day of the subscription period cannot be guaranteed if mailed.

NOMINEE-REGISTERED SHAREHOLDERS

Shareholders whose holdings of shares in the Company are nominee-registered with a bank or other nominee will not receive an issue statement. Instead, subscription and payment shall be made in accordance with instructions from the respective bank or nominee. Please note that when exercising unit rights through a bank or nominee, this should be done early during the subscription period, as each bank/nominee may establish different deadlines for subscription.

SUBSCRIPTION WITHOUT PREFERENTIAL RIGHT

Subscription for units without preferential rights shall take place during the same period as subscription for units with preferential rights, i.e., from and including 9 July 2026. The Board of Directors reserves the right, under all circumstances, to extend the subscription period and the payment period. Any such extension shall be announced no later than the last day of the subscription period and disclosed by the Company.

Applications to subscribe for units without preferential rights shall be made via Vator Securities' website, <https://vatorsecurities.se/sv/offers>. For nominee-registered shareholders, applications to subscribe for units without preferential rights shall be submitted to the respective nominee and in accordance with the nominee's instructions, or, if the holding is registered with multiple nominees, to each of them. In order to invoke subsidiary preferential rights, the subscription must be carried out through the nominee, as otherwise there is no possibility of identifying a particular subscriber who has subscribed for units both with and without the support of unit rights.

Incomplete or incorrectly completed subscription applications may be disregarded. Only one application for "Subscription without unit rights" may be submitted. Subscription must be made no later than 23 July 2026. The application is binding.

SUBSCRIPTION FROM ACCOUNTS SUBJECT TO SPECIFIC RULES

Please note that investors holding securities in accounts subject to specific rules regarding securities transactions, such as an Investment Savings Account (ISK) or a Capital Insurance Account (KF), must consult the bank or nominee administering the account to determine whether acquisition of securities under the Offering is permitted. In such cases, the application must be made in consultation with the bank/nominee administering the account.

SUBSCRIPTIONS OF EUR 15,000 OR MORE

If the subscription amount equals or exceeds EUR 15,000, an anti-money laundering (AML) form must be completed and submitted to Vator Securities in accordance with the Swedish Anti-Money Laundering and Terrorist Financing Act (2017:630). Please note that Vator Securities cannot deliver securities, even if payment has been received, until the AML review has been completed and the required documentation has been received by Vator Securities.

SHAREHOLDERS RESIDENT OUTSIDE OF SWEDEN

Shareholders resident outside Sweden (excluding shareholders resident in the United States, Australia, Japan, Canada, New Zealand, South Africa, Hong Kong, Switzerland, Singapore, South Korea, Russia, Belarus, or any other jurisdiction where participation would require additional prospectuses, registrations, or measures beyond those required under Swedish law) who are entitled to subscribe for units in the Rights Issue may contact Vator Securities for information regarding subscription and payment.

Due to restrictions under securities laws in the United States, Australia, Japan, Canada, New Zealand, South Africa, Hong Kong, Switzerland, Singapore, South Korea, Russia, Belarus, or any other jurisdiction where participation would require additional prospectuses, registrations, or measures beyond those required under Swedish law, no unit rights will be offered to holders with registered addresses in any of these jurisdictions. Accordingly, no offer to subscribe for units in the Company is being made to shareholders in such jurisdictions.

Notwithstanding any other provision in this document, the pre-printed issue statement, or the application forms, the Company reserves the right to permit any person to apply for new securities in the Rights Issue if the Company is satisfied that the relevant transaction is exempt from, or not subject to, the laws or regulations giving rise to the restrictions in question.

ALLOCATION OF UNITS SUBSCRIBED FOR WITHOUT PREFERENTIAL RIGHTS

If not all units are subscribed for with the support of unit rights, the Board of Directors shall, within the maximum amount of the Rights Issue, determine the allocation of units to those who have subscribed for units without preferential rights. Such allocation shall primarily be made to subscribers who have subscribed for units with the support of unit rights, regardless of whether the subscriber was a shareholder on the record date or not, and, in the event of oversubscription, pro rata in relation to the number of units subscribed for with the support of unit rights. Secondly, allocation shall be made to those who have subscribed for units without the support of unit rights and, in the event of oversubscription, pro rata in relation to the number of units applied for, and, to the extent allocation cannot be made on a pro rata basis, by drawing of lots. Thirdly, allocation shall be made to the guarantor in accordance with the terms of the issued underwriting commitment.

NOTICE OF ALLOCATION OF UNITS SUBSCRIBED FOR WITHOUT PREFERENTIAL RIGHTS

Notification of any allocation of units subscribed for without preferential rights will be provided by sending a contract note (avräkningsnota) via e-mail. Contract notes are expected to be distributed as soon as possible following the end of the subscription period, and payment must be made no later than three banking days thereafter in accordance with the instructions provided in the contract note. Please note that there is no possibility to debit the amount from a specified custody account. If payment is not made on time, the units may be transferred to another party. Should the sale price in such transfer be lower than the subscription price under the Offering, the person who was originally allocated the units may be liable for all or part of the difference. No notification will be sent to applicants who do not receive an allocation.

PUBLICATION OF THE OUTCOME OF THE RIGHTS ISSUE

The outcome of the Rights Issue is expected to be announced on 27 July 2026, or as soon as possible after the subscription period has ended. The Company will publish the results of the Rights Issue through a press release.

PAID SUBSCRIBED UNITS (BTU'S)

Subscription through payment will be registered with Euroclear as soon as possible, which normally occurs within a few banking days following payment. Thereafter, directly registered subscribers will receive a VP advice note confirming that paid subscribed units (BTUs) have been credited to the subscriber's VP account. The subscribed units will be recorded as BTUs in the VP account until the Rights Issue has been registered with the Swedish Companies Registration Office (Bolagsverket). Shareholders whose holdings are registered in a custody account with a bank or nominee will receive information from their respective nominee.

TRADING IN BTU'S

Trading in BTUs will take place on Nasdaq First North Growth Market from 9 July 2026 until the Rights Issue has been registered with the Swedish Companies Registration Office (Bolagsverket). Subscribed units will remain recorded as BTUs in the subscriber's VP account or custody account until registration of the Rights Issue with Bolagsverket, which is expected to occur in mid-August 2026.

DELIVERY OF SHARES AND WARRANTS

As soon as the Rights Issue has been registered with Bolagsverket, the BTUs will be converted into shares and warrants without any separate notification from Euroclear. Please note that the issue may be registered in stages (partial registration) with Bolagsverket.

TRADING IN THE SHARE

The Company's shares are listed on Nasdaq First North Growth Market. The shares are traded under the ticker symbol "PROGEN" and have ISIN code SE0023261532.

The new securities will be admitted to trading in connection with the conversion of BTUs into shares and warrants.

RIGHT TO DIVIDENDS

The new shares shall carry entitlement to dividends for the first time on the first dividend record date occurring after the new shares have been registered with Bolagsverket. The new shares carry the same dividend rights as the existing shares.

DILUTION

Through the Rights Issue, the Company's share capital may initially increase by a maximum of SEK 47,351,456.80 through the issuance of up to 473,514,568 shares, corresponding to approximately 88.9 percent of the votes and capital in the Company. The dilution is based on the number of issued shares following full subscription of the Rights Issue. Upon full exercise of warrants of series TO6 issued within the framework of the Rights Issue, the share capital may increase by an additional maximum of SEK 11,837,864.20, corresponding to a further approximately 18.2 percent of the votes and capital in the Company. Upon full exercise of warrants of series TO7 issued within the framework of the Rights Issue, the share capital may increase by an additional maximum of SEK 23,675,728.40, corresponding to a further approximately 26.7 percent of the votes and capital in the Company.

POSSIBLE ADJUSTMENT OF THE SUBSCRIPTION PRICE AND SUBSCRIPTION ENTITLEMENT

The subscription price and/or the number of shares that the warrants entitle the holder to subscribe for may be recalculated in connection with, for example, a bonus issue or a new share issue. Should such a recalculation become relevant, the Company will publish further information by way of a press release on its website (www.prostatypegenomics.com).

SUBSCRIPTIONS RESULTING IN A NOTIFICATION OBLIGATION UNDER THE FDI ACT

The Swedish Foreign Direct Investment Screening Act (2023:560) (the "FDI Act") applies to the Company's operations. If a subscription for units would result in any of the investor's holdings exceeding the thresholds of 10, 20, 30, 50, 65, or 90 percent of the voting rights in the Company, the investor must notify its investment in accordance with the FDI Act. This notification requirement does not apply if the investor subscribes for units with preferential rights in proportion to the number of shares held by the investor on the record date, 7 July 2026.

INFORMATION REGARDING LEI AND NCI NUMBERS

Pursuant to the securities trading regulations that entered into force on 3 January 2018 (MiFID II/MiFIR), all investors must have a global identification code in order to conduct securities transactions. These requirements mean that legal entities must obtain a Legal Entity Identifier (LEI), while natural persons must determine their National Client Identifier (NCI), in order to subscribe for units in the Rights Issue.

Please note that the subscriber's legal status determines whether an LEI code or an NCI number is required, and that Vator Securities may be prevented from carrying out the transaction if the applicable LEI code or NCI number is not provided.

Legal entities that need to obtain an LEI code may contact any of the service providers available in the market. Information regarding the global LEI system is available at gleif.org. For natural persons holding only Swedish citizenship, the NCI number consists of the designation "SE" followed by the individual's Swedish personal identity number. If the individual holds multiple citizenships or a citizenship other than Swedish citizenship, the NCI may consist of a different type of identifier.

Any person intending to subscribe for units in the Rights Issue is encouraged to apply for an LEI code (legal entities) or determine their NCI number (natural persons) well in advance in order to be eligible to participate in the Rights Issue and/or receive allocation of units subscribed for without the support of unit rights.

UNDERWRITING COMMITMENT AND SUBSCRIPTION COMMITMENTS

In total, the Rights Issue is covered by subscription commitments and underwriting undertakings amounting to approximately SEK 43.2 million, corresponding to approximately 91.3 percent of the Rights Issue. Of this amount, approximately SEK 34 million, corresponding to approximately 71.9 percent, relates to bottom- and top-down underwriting undertakings and approximately SEK 9.2 million, corresponding to approximately 19.4 percent, relates to subscription commitments. For a complete list of parties that have entered into underwriting and subscription commitment agreements, reference is made to the information memorandum.

OTHER

The Board of Directors of the Company is not entitled to cancel, withdraw, or temporarily suspend the offer to subscribe for new shares in the Company in accordance with the terms of the prospectus. If an excess amount has been paid by a subscriber for subscribed units, Vator Securities will arrange for the excess amount to be refunded. In such case, Vator Securities will contact the subscriber to obtain bank account details for repayment. No interest will be paid on excess amounts. Subscription for new units is irrevocable, and the subscriber may not cancel or modify a subscription for new units. Incomplete or incorrectly completed applications/subscriptions may be disregarded. If payment for subscribed units is late, insufficient, or made incorrectly, the application may be disregarded or subscription may be made for a lower amount. Paid amounts not used will be refunded. If multiple applications/subscriptions of the same category are submitted, only the most recently received application/subscription by Vator Securities will be considered. Late payments below SEK 100 will be refunded only upon request.

ISSUING AGENT

Vator Securities acts as issuing agent in connection with the Rights Issue.